Richard D. Braatz, PhD

Novartis-MIT Center
Edwin R. Gilliland Prof of Chemical Engineering
Richard D. Braatz is the Edwin R. Gilliland Professor of Chemical Engineering at the Massachusetts Institute of Technology (MIT) where he does research in the design and control of continuous (bio)pharmaceutical manufacturing systems. He leads the Quality-by-Design (QbD) and control systems activities in many (bio)pharmaceutical manufacturing efforts at MIT. He has consulted or collaborated with more than 20 companies including Novartis, Pfizer, Merck, Biogen, and Amgen.

Related Articles

Effect of Industry 4.0 enablers on the product life cycle.
Features
Data Science for Pharma 4.0™: Drug Development, & Production—Part 2

This second of a two-part series explores digital transformation and digitalization in the biopharmaceutical industry with information about how data science enables digitalization along the product life cycle. (Part 1 was published in the March-April 2021 issue of Pharmaceutical Engineering.Herwig, C., et al. “Data Science for Pharma 4.0™, Drug Development, and Production—Part...

Effect of Indutry 4.0 enablers on the manufacturing process chain. Upper arrow: Conventional approach. Lower arrow: Perceived extended process chain using IIoT enablers.
Features
Data Science for Pharma 4.0™, Drug Development, & Production—Part 1

Digital transformation and digitalization are on the agenda for all organizations in the biopharmaceutical industry. But what are the main enablers of intelligent manufacturing? We hypothesize that data science–derived manufacturing process and product understanding is the main driver of digitalization in the bioprocessing industry for biologics manufacturing. In this article, the first of a...